Susanne Schnittger

Summary

Affiliation: University of Munich
Country: Germany

Publications

  1. ncbi request reprint Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease
    Susanne Schnittger
    Department of Internal Medicine III, University of Munich, Germany
    Blood 100:59-66. 2002
  2. ncbi request reprint New score predicting for prognosis in PML-RARA+, AML1-ETO+, or CBFBMYH11+ acute myeloid leukemia based on quantification of fusion transcripts
    Susanne Schnittger
    Laboratory for Leukemia Diagnostics, Department of Internal Medicine III, University Hospital Grosshadern, Ludwig Maximilians University, Marchioninistrasse 15, 81377 Munich, Germany
    Blood 102:2746-55. 2003
  3. ncbi request reprint FLT3 length mutations as marker for follow-up studies in acute myeloid leukaemia
    Susanne Schnittger
    Laboratory for Leukaemia Diagnostics, Department of Internal Medicine III, Ludwig Maximilians University of Munich, University Hospital Grosshadern, Munich, Germany
    Acta Haematol 112:68-78. 2004
  4. ncbi request reprint Detailed analysis of FLT3 expression levels in acute myeloid leukemia
    Florian Kuchenbauer
    Department of Internal Medicine III, Ludwig Maximilians University of Munich, University Hospital Grosshadern, Munich, Germany
    Haematologica 90:1617-25. 2005
  5. doi request reprint Toward a comprehensive prognostic scoring system in chronic lymphocytic leukemia based on a combination of genetic parameters
    Claudia Haferlach
    MLL Munich Leukemia Laboratory, Munich, Germany
    Genes Chromosomes Cancer 49:851-9. 2010
  6. ncbi request reprint Mutations in the tyrosine kinase domain of FLT3 define a new molecular mechanism of acquired drug resistance to PTK inhibitors in FLT3-ITD-transformed hematopoietic cells
    Ksenia Bagrintseva
    Department of Medicine III, University Hospital Grosshadern, Luwig Maximilians University, Munich, Germany
    Blood 103:2266-75. 2004
  7. ncbi request reprint The influence of age on prognosis of de novo acute myeloid leukemia differs according to cytogenetic subgroups
    Claudia Schoch
    Laboratory for Leukemia Diagnostics, Department of Internal Medicine III, University Hospital Grosshadern, Ludwig Maximilians University, Munich, Germany
    Haematologica 89:1082-90. 2004
  8. pmc Frequency and prognostic impact of CEBPA proximal, distal and core promoter methylation in normal karyotype AML: a study on 623 cases
    Annette Fasan
    MLL Munich Leukemia Laboratory, Munich, Germany
    PLoS ONE 8:e54365. 2013
  9. ncbi request reprint Impact of FLT3 mutations and promyelocytic leukaemia-breakpoint on clinical characteristics and prognosis in acute promyelocytic leukaemia
    Florian Kuchenbauer
    Laboratory for Leukemia Diagnostics, Department of Internal Medicine III, Ludwig Maximilians University of Munich, University Hospital Grosshadern, Munich, Germany
    Br J Haematol 130:196-202. 2005
  10. doi request reprint Minimal residual disease levels assessed by NPM1 mutation-specific RQ-PCR provide important prognostic information in AML
    Susanne Schnittger
    MLL Munich Leukemia Laboratory, Munich, Germany
    Blood 114:2220-31. 2009

Detail Information

Publications107 found, 100 shown here

  1. ncbi request reprint Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease
    Susanne Schnittger
    Department of Internal Medicine III, University of Munich, Germany
    Blood 100:59-66. 2002
    ..6 months; P =.0072) because of a higher relapse rate. Besides the importance of FLT3-LM for biologic and clinical characterization of AML, we show its value as a marker for disease monitoring based on 120 follow-up samples of 34 patients...
  2. ncbi request reprint New score predicting for prognosis in PML-RARA+, AML1-ETO+, or CBFBMYH11+ acute myeloid leukemia based on quantification of fusion transcripts
    Susanne Schnittger
    Laboratory for Leukemia Diagnostics, Department of Internal Medicine III, University Hospital Grosshadern, Ludwig Maximilians University, Marchioninistrasse 15, 81377 Munich, Germany
    Blood 102:2746-55. 2003
    ..By combining the transcription ratios at these 2 checkpoints, a new powerful prognostic score has been established...
  3. ncbi request reprint FLT3 length mutations as marker for follow-up studies in acute myeloid leukaemia
    Susanne Schnittger
    Laboratory for Leukaemia Diagnostics, Department of Internal Medicine III, Ludwig Maximilians University of Munich, University Hospital Grosshadern, Munich, Germany
    Acta Haematol 112:68-78. 2004
    ..Using conventional PCR it clearly could be shown that for most of the patients positive at presentation FLT3-LM is a reliable PCR marker for monitoring treatment response. Even an early detection of relapse was possible in some cases...
  4. ncbi request reprint Detailed analysis of FLT3 expression levels in acute myeloid leukemia
    Florian Kuchenbauer
    Department of Internal Medicine III, Ludwig Maximilians University of Munich, University Hospital Grosshadern, Munich, Germany
    Haematologica 90:1617-25. 2005
    ..Although new FLT3 mutations are being increasing by investigated, the role of FLT3 expression levels in wild type as well as in mutated FLT3 has only been infrequently addressed...
  5. doi request reprint Toward a comprehensive prognostic scoring system in chronic lymphocytic leukemia based on a combination of genetic parameters
    Claudia Haferlach
    MLL Munich Leukemia Laboratory, Munich, Germany
    Genes Chromosomes Cancer 49:851-9. 2010
    ..The proposed scoring systems for OS and TTT based on a combination of genetic markers improve the separation of prognostic subgroups in CLL already early in the course of the disease...
  6. ncbi request reprint Mutations in the tyrosine kinase domain of FLT3 define a new molecular mechanism of acquired drug resistance to PTK inhibitors in FLT3-ITD-transformed hematopoietic cells
    Ksenia Bagrintseva
    Department of Medicine III, University Hospital Grosshadern, Luwig Maximilians University, Munich, Germany
    Blood 103:2266-75. 2004
    ..These findings provide a molecular basis for the evaluation of clinical resistance to FLT3 PTK inhibitors in patients with AML...
  7. ncbi request reprint The influence of age on prognosis of de novo acute myeloid leukemia differs according to cytogenetic subgroups
    Claudia Schoch
    Laboratory for Leukemia Diagnostics, Department of Internal Medicine III, University Hospital Grosshadern, Ludwig Maximilians University, Munich, Germany
    Haematologica 89:1082-90. 2004
    ..The 1225 patients with de novo AML were separated according to age as follows: A1: 16 to 49 years (n=442), A2: 50 to 59 years (n=246), A3: 60-69 years (n=333), A4: 70 years and older (n=204)...
  8. pmc Frequency and prognostic impact of CEBPA proximal, distal and core promoter methylation in normal karyotype AML: a study on 623 cases
    Annette Fasan
    MLL Munich Leukemia Laboratory, Munich, Germany
    PLoS ONE 8:e54365. 2013
    ..In conclusion, the presence of aberrant CEBPA PM is associated with distinct biological features but impact on outcome is weak...
  9. ncbi request reprint Impact of FLT3 mutations and promyelocytic leukaemia-breakpoint on clinical characteristics and prognosis in acute promyelocytic leukaemia
    Florian Kuchenbauer
    Laboratory for Leukemia Diagnostics, Department of Internal Medicine III, Ludwig Maximilians University of Munich, University Hospital Grosshadern, Munich, Germany
    Br J Haematol 130:196-202. 2005
    ..6%) and associated with a significant lower overall survival (P = 0.0339). In addition, cases with bcr3 showed a tendency for a worse event-free survival (P = 0.0795) compared with the bcr1 group...
  10. doi request reprint Minimal residual disease levels assessed by NPM1 mutation-specific RQ-PCR provide important prognostic information in AML
    Susanne Schnittger
    MLL Munich Leukemia Laboratory, Munich, Germany
    Blood 114:2220-31. 2009
    ..Similar results were obtained in patients undergoing second-line chemotherapy or allogeneic stem cell transplantation...
  11. ncbi request reprint Determination of relapse risk based on assessment of minimal residual disease during complete remission by multiparameter flow cytometry in unselected patients with acute myeloid leukemia
    Wolfgang Kern
    Laboratory for Leukemia Diagnostics, Ludwig Maximilians University, University Hospital Grosshadern, Department of Internal Medicine III, 81366 Muenchen, Germany
    Blood 104:3078-85. 2004
    ..MFC-based quantification of MRD reveals important prognostic information in unselected patients with AML in addition to cytogenetics and should be further evaluated and used in clinical trials...
  12. doi request reprint Amount of bone marrow blasts is strongly correlated to NPM1 and FLT3-ITD mutation rate in AML with normal karyotype
    Torsten Haferlach
    MLL Munich Leukemia Laboratory, Max Lebsche Platz 31, 81377 Munich, Germany
    Leuk Res 36:51-8. 2012
    ..Mean WBC count was highest in NPM1-mut/FLT3-ITD-positive and lowest in NPM1-wildtype/FLT3-ITD-negative patients (p<0.0001); similar for BM blasts. Therefore, FLT3-ITD and NPM1mut might synergistically stimulate blast proliferation...
  13. ncbi request reprint Correlation of protein expression and gene expression in acute leukemia
    Wolfgang Kern
    Laboratory for Leukemia Diagnostics, Ludwig Maximilians University, University Hospital Grosshadern, Department of Internal Medicine III, Munich, Germany
    Cytometry B Clin Cytom 55:29-36. 2003
    ..In the future, diagnostic procedures may include oligonucleotide microarray analysis (MA) to detect expression patterns of large numbers of specific genes...
  14. doi request reprint Associations between imatinib resistance conferring mutations and Philadelphia positive clonal cytogenetic evolution in CML
    Susanne Schnittger
    MLL Munich Leukemia Laboratory GmbH, Munich, Germany
    Genes Chromosomes Cancer 49:910-8. 2010
    ..Therefore, some KD mutations (e.g., T315I) might be associated with higher genetic instability paving the way to additional cytogenetic and molecular genetic events...
  15. doi request reprint Three novel cytogenetically cryptic EVI1 rearrangements associated with increased EVI1 expression and poor prognosis identified in 27 acute myeloid leukemia cases
    Claudia Haferlach
    MLL Munich Leukemia Laboratory, Munich, Germany
    Genes Chromosomes Cancer 51:1079-85. 2012
    ..Screening for cryptic EVI1 rearrangements by FISH may be particularly appropriate in CN-AML with elevated EVI1 expression or in AML/MDS patients with chromosome 7 abnormalities...
  16. doi request reprint Gene expression of BAALC, CDKN1B, ERG, and MN1 adds independent prognostic information to cytogenetics and molecular mutations in adult acute myeloid leukemia
    Claudia Haferlach
    MLL Munich Leukemia Laboratory, Munich, Germany
    Genes Chromosomes Cancer 51:257-65. 2012
    ..4%, 56.4%, 34.0%, 12.6%; mEFS: n.r., 18.1 months, 8.7 months, 2.5 months). The impact on outcome of this score was independent of NPM1mut/FLT3-ITD- status, MLL-PTD, and age...
  17. ncbi request reprint Advanced age and high initial WBC influence the outcome of inv(3) (q21q26)/t(3;3) (q21;q26) positive AML
    Martin Weisser
    Medical Department III, Klinikum Grosshadern, Ludwig Maximilians University, Munich, Germany
    Leuk Lymphoma 48:2145-51. 2007
    ..Our data (1) confirm that inv(3)/t(3;3) AML has a poor prognosis (2) show that age and initial WBC are risk factors for prognosis; (3) suggest that this group may benefit from allogeneic stem cell transplantation...
  18. doi request reprint RQ-PCR based WT1 expression in comparison to BCR-ABL quantification can predict Philadelphia negative clonal evolution in patients with imatinib-treated chronic myeloid leukaemia
    Susanne Schnittger
    MLL Munich Leukaemia Laboratory GmbH, Munich, Germany
    Br J Haematol 146:665-8. 2009
    ..Thus, increasing WT1 levels in molecular responders may indicate Ph-negative clonal cytogenetic evolution during imatinib treatment...
  19. ncbi request reprint Detection of minimal residual disease in unselected patients with acute myeloid leukemia using multiparameter flow cytometry for definition of leukemia-associated immunophenotypes and determination of their frequencies in normal bone marrow
    Wolfgang Kern
    Laboratory for Leukemia Diagnostics, Ludwig Maximilians University, University Hospital Grosshadern, Dept of Internal Medicine III, Muenchen, Germany
    Haematologica 88:646-53. 2003
    ..The present analysis aimed at improving the applicability of this approach to more patients with AML...
  20. doi request reprint AML with mutated NPM1 carrying a normal or aberrant karyotype show overlapping biologic, pathologic, immunophenotypic, and prognostic features
    Claudia Haferlach
    Munich Leukemia Laboratory GmbH, Munich, Germany
    Blood 114:3024-32. 2009
    ....
  21. ncbi request reprint KIT-D816 mutations in AML1-ETO-positive AML are associated with impaired event-free and overall survival
    Susanne Schnittger
    Laboratory of Leukemia Diagnostics and Clinical Cooperative Group Leukemia, Department of Medicine III, University Hospital Grosshadern, Ludwig Maximilians University, Munich, Germany
    Blood 107:1791-9. 2006
    ..Patients with KIT-D816-positive/AML1-ETO-positive AML might benefit from early intensification of treatment or combination of conventional chemotherapy with KIT PTK inhibitors...
  22. ncbi request reprint Prognostic impact of early response to induction therapy as assessed by multiparameter flow cytometry in acute myeloid leukemia
    Wolfgang Kern
    Laboratory for Leukemia Diagnostics, Dept of Internal Medicine III, University Hospital Grosshadern, Ludwig Maximilians University, 81366 Muenchen, Germany
    Haematologica 89:528-40. 2004
    ..We improved the identification of this parameter by implementing multiparameter flow cytometry to quantify bone marrow cells carrying leukemia-associated immunophenotypes (LAIP)...
  23. ncbi request reprint D324N single-nucleotide polymorphism in the FLT3 gene is associated with higher risk of myeloid leukemias
    Susanne Schnittger
    Laboratory for Leukemia Diagnostics, Department of Internal Medicine III, University Hospital Grosshadern, Munich, Germany
    Genes Chromosomes Cancer 45:332-7. 2006
    ..001). In addition, 21 of 234 CML (9.0%) and 7 of 155 ALL (4.5%) cases carried the FLT3 D324N. Our data suggest that the FLT3 D324N variant might be associated with a predisposition to different subtypes of leukemia...
  24. doi request reprint The molecular profile of adult T-cell acute lymphoblastic leukemia: mutations in RUNX1 and DNMT3A are associated with poor prognosis in T-ALL
    Vera Grossmann
    MLL Munich Leukemia Laboratory, Max Lebsche Platz 31, 81377 Munich, Germany
    Genes Chromosomes Cancer 52:410-22. 2013
    ..027) and DNMT3A (P = 0.005) mutations with shorter overall survival was observed. In conclusion, RUNX1 and DNMT3A are frequently mutated in T-ALL and are associated with poor prognosis in early T-ALL...
  25. doi request reprint A novel hierarchical prognostic model of AML solely based on molecular mutations
    Vera Grossmann
    MLL Munich Leukemia Laboratory, Munich, Germany
    Blood 120:2963-72. 2012
    ..9%); and (5) very unfavorable: TP53 mutation (n = 80; OS at 3 years: 0%; P < .001). This comprehensive molecular characterization provides a more powerful model for prognostication than cytogenetics...
  26. pmc Molecular analyses of 15,542 patients with suspected BCR-ABL1-negative myeloproliferative disorders allow to develop a stepwise diagnostic workflow
    Susanne Schnittger
    MLL Munich Leukemia Laboratory, Munich, Germany
    Haematologica 97:1582-5. 2012
    ..In cases in which a myeloproliferative neoplasm cannot be established, analysis for TET2, CBL and EZH2 mutations may be indicated...
  27. doi request reprint ETV6 rearrangements are recurrent in myeloid malignancies and are frequently associated with other genetic events
    Claudia Haferlach
    MLL Munich Leukemia Laboratory, Munich, Germany
    Genes Chromosomes Cancer 51:328-37. 2012
    ..Our study confirms the variety of ETV6 rearrangements in AML, MDS, and MPNs often in association with other genetic events. Prognosis of ETV6 rearranged de novo AML seems to be intermediate, which should be independently confirmed...
  28. doi request reprint Whole-exome sequencing identifies somatic mutations of BCOR in acute myeloid leukemia with normal karyotype
    Vera Grossmann
    MLL Munich Leukemia Laboratory, Munich, Germany
    Blood 118:6153-63. 2011
    ..Finally, BCOR mutations tended to be associated with an inferior outcome in a cohort of 422 CN-AML patients (25.6% vs 56.7% overall survival at 2 years; P = .032). Our results for the first time implicate BCOR in CN-AML pathogenesis...
  29. ncbi request reprint KIT exon 8 mutations associated with core-binding factor (CBF)-acute myeloid leukemia (AML) cause hyperactivation of the receptor in response to stem cell factor
    Tobias M Kohl
    Department of Medicine III, University Hospital Grosshadern, CCG Leukemia, GSF National Research Center for Environment and Health, Marchioninistrasse 25, 81377 Munich, Germany
    Blood 105:3319-21. 2005
    ..Our data show that KIT exon 8 mutations represent gain-of-function mutations and might represent a new molecular target for treatment of CBF leukemias...
  30. ncbi request reprint Rapid diagnostic approach to PML-RARalpha-positive acute promyelocytic leukemia
    Claudia Schoch
    Department of Internal Medicine III, University Hospital Grosshadern, Ludwig Maximilians University, Munich, Germany
    Hematol J 3:259-63. 2002
    ..The introduction of all trans retinoic acid (ATRA) into treatment protocols has improved the outcome of APL dramatically. Therefore, it is essential to establish the diagnosis of APL as quickly and as reliably as possible...
  31. ncbi request reprint A new prognostic score for patients with acute myeloid leukemia based on cytogenetics and early blast clearance in trials of the German AML Cooperative Group
    Torsten Haferlach
    Ludwig Maximilians University, University Hospital Grosshadern, Dept of Internal Medicine III, Munchen, Germany
    Haematologica 89:408-18. 2004
    ..To refine cytogenetically based risk-stratification in acute myeloid leukemia (AML)...
  32. ncbi request reprint Implications of NRAS mutations in AML: a study of 2502 patients
    Ulrike Bacher
    Munich Leukemia Laboratory, Department of Internal Medicine III, University Hospital Munich, Ludwig Maximilians University, Max Lebsche Platz 31, 81377 Munich, Germany
    Blood 107:3847-53. 2006
    ..However, there was a trend to better survival in most subgroups, especially when other molecular markers (FLT3-LM, MLL-PTD, and NPM) were taken into account...
  33. ncbi request reprint A comparison of donor lymphocyte infusions or imatinib mesylate for patients with chronic myelogenous leukemia who have relapsed after allogeneic stem cell transplantation
    Martin Weisser
    Department of Internal Medicine III, University of Munich, Klinikum Grosshadern, Munich, Germany
    Haematologica 91:663-6. 2006
    ..Imatinib therapy resulted in a higher incidence of relapse and inferior leukemia-free survival (p=0.006 and p=0.016, respectively). These data suggest that imatinib alone probably does not cure relapse after HSCT...
  34. ncbi request reprint Comparison of mRNA abundance quantified by gene expression profiling and percentage of positive cells using immunophenotyping for diagnostic antigens in acute and chronic leukemias
    Wolfgang Kern
    MLL Munich Leukemia Laboratory, Munich, Germany
    Cancer 107:2401-7. 2006
    ....
  35. ncbi request reprint Pattern robustness of diagnostic gene expression signatures in leukemia
    Alexander Kohlmann
    Laboratory for Leukemia Diagnostics, University Hospital Grosshadern, Ludwig Maximilians University, Munich, Germany
    Genes Chromosomes Cancer 42:299-307. 2005
    ....
  36. ncbi request reprint Arginine 595 is duplicated in patients with acute leukemias carrying internal tandem duplications of FLT3 and modulates its transforming potential
    Sridhar Vempati
    Clinical Cooperative Group Leukemia, GSF National Research Center for Environment and Health, Munich, Germany
    Blood 110:686-94. 2007
    ..Our data provide important insights into the molecular mechanism of transformation by FLT3-ITDs and show that duplication of R595 is important for the leukemic potential of FLT3-ITDs...
  37. ncbi request reprint Four-fold staining including CD45 gating improves the sensitivity of multiparameter flow cytometric assessment of minimal residual disease in patients with acute myeloid leukemia
    Wolfgang Kern
    Laboratory for Leukemia Diagnostics, Department of Internal Medicine III, Ludwig Maximilians University, University Hospital Grosshadern, 81366 Muenchen, Germany
    Hematol J 5:410-8. 2004
    ..08 log (range, 1.22-4.01) and 2.28 log (range, 1.12-3.34) with and without CD45 gating. CD45 gating improves the sensitivity of MFC-based MRD monitoring in AML by 1 log...
  38. doi request reprint Multilineage dysplasia (MLD) in acute myeloid leukemia (AML) correlates with MDS-related cytogenetic abnormalities and a prior history of MDS or MDS/MPN but has no independent prognostic relevance: a comparison of 408 cases classified as "AML not otherwis
    Miriam Miesner
    MLL Munich Leukemia Laboratory, Munich, Germany
    Blood 116:2742-51. 2010
    ..Thus, MLD alone showed no independent clinical effect, whereas cytogenetics and MDS history were prognostically relevant...
  39. doi request reprint CEBPA double-mutated acute myeloid leukaemia harbours concomitant molecular mutations in 76·8% of cases with TET2 and GATA2 alterations impacting prognosis
    Vera Grossmann
    MLL Munich Leukemia Laboratory, Munich, Germany
    Br J Haematol 161:649-58. 2013
    ..Further, a distinct gene expression profile (GEP) was confirmed for CEBPAdm versus CEBPAsm or CEBPA wild-type cases while no significant changes in GEP were observed related to additional mutations within the CEBPAdm AML...
  40. ncbi request reprint Loss of genetic material is more common than gain in acute myeloid leukemia with complex aberrant karyotype: a detailed analysis of 125 cases using conventional chromosome analysis and fluorescence in situ hybridization including 24-color FISH
    Claudia Schoch
    Department of Internal Medicine III, University Hospital Grosshadern, Ludwig Maximilians University, Munich, Germany
    Genes Chromosomes Cancer 35:20-9. 2002
    ....
  41. doi request reprint Monoclonal B-cell lymphocytosis is closely related to chronic lymphocytic leukaemia and may be better classified as early-stage CLL
    Wolfgang Kern
    MLL Munich Leukaemia Laboratory, Max Lebsche Platz 31, Munich, Germany
    Br J Haematol 157:86-96. 2012
    ..These data emphasize a close relationship between MBL and CLL regarding clinically relevant parameters and provide no evidence to strictly separate these entities by a distinct threshold of clonal B-cells...
  42. doi request reprint Diversity of the juxtamembrane and TKD1 mutations (exons 13-15) in the FLT3 gene with regards to mutant load, sequence, length, localization, and correlation with biological data
    Susanne Schnittger
    MLL Munich Leukemia Laboratory, Munich, Germany
    Genes Chromosomes Cancer 51:910-24. 2012
    ..In conclusion, FLT3-mutations are extremely heterogenous with mutation load being the most relevant parameter...
  43. ncbi request reprint Molecular characterization of acute leukemias by use of microarray technology
    Alexander Kohlmann
    Laboratory for Leukemia Diagnostics, Department of Internal Medicine III, Ludwig Maximilians University, Munich, Germany
    Genes Chromosomes Cancer 37:396-405. 2003
    ..These data support a possible future application of microarray technology for classification of the acute leukemias...
  44. ncbi request reprint AML M3 and AML M3 variant each have a distinct gene expression signature but also share patterns different from other genetically defined AML subtypes
    Torsten Haferlach
    Laboratory for Leukemia Diagnostics, University Hospital Grosshadern, Ludwig Maximilians University, Munich, Germany
    Genes Chromosomes Cancer 43:113-27. 2005
    ..0001), may partly contribute to the different phenotypes. However, linear regression analysis demonstrated that genes differentially expressed between M3 and M3v did not correlate with FLT3-LM...
  45. ncbi request reprint Evaluation of complete disease remission in acute myeloid leukemia: a prospective study based on cytomorphology, interphase fluorescence in situ hybridization, and immunophenotyping during follow-up in patients with acute myeloid leukemia
    Ulrike Bacher
    Laboratory for Leukemia Diagnostics, Department for Internal Medicine III, Klinikum Grosshadern, Ludwig Maximilians University, Munich, Germany
    Cancer 106:839-47. 2006
    ..The detection of minimal residual disease (MRD) for predicting prognosis and for therapeutic planning still are under discussion...
  46. ncbi request reprint Trisomy 13 is strongly associated with AML1/RUNX1 mutations and increased FLT3 expression in acute myeloid leukemia
    Frank Dicker
    Munich Leukemia Laboratory GmbH, Munich, Germany
    Blood 110:1308-16. 2007
    ..The results of the present study indicate that in the absence of FLT3 mutations, FLT3 overexpression might be a mechanism for FLT3 activation, which cooperates with RUNX1 mutations in leukemogenesis...
  47. pmc CDKN1B, encoding the cyclin-dependent kinase inhibitor 1B (p27), is located in the minimally deleted region of 12p abnormalities in myeloid malignancies and its low expression is a favorable prognostic marker in acute myeloid leukemia
    Claudia Haferlach
    MLL, Munich Leukemia Laboratory, Max Lebsche Platz 31, 81377 Munich, Germany
    Haematologica 96:829-36. 2011
    ..Alterations of the short arm of chromosome 12 (12p) occur in various hematologic malignancies and ETV6 and CDKN1B, which are located on 12p, have been implicated as leukemogenic genes of interest...
  48. ncbi request reprint Cytogenetic profile in de novo acute myeloid leukemia with FAB subtypes M0, M1, and M2: a study based on 652 cases analyzed with morphology, cytogenetics, and fluorescence in situ hybridization
    Mirjam Klaus
    Department of Internal Medicine III, Laboratory for Leukemia Diagnostics, Ludwig Maximilians University, Marchioninistrasse 15, 81377 Munich, Germany
    Cancer Genet Cytogenet 155:47-56. 2004
    ..In conclusion, t(8;21), +11, +13, and +14 are strongly associated with AML M0, M1, and M2. The FISH screening analyses identified abnormalities in an additional 3% in normal karyotypes...
  49. doi request reprint RUNX1 mutations are frequent in de novo AML with noncomplex karyotype and confer an unfavorable prognosis
    Susanne Schnittger
    Munich Leukemia Laboratory, Max Lebsche Platz 31, Munich, Germany
    Blood 117:2348-57. 2011
    ..Multivariate analysis showed independent prognostic relevance for overall survival for RUNX1mut (P = .029), FLT3-ITD (P = .003), age (P < .001), and white blood cell count (P < .002)...
  50. pmc Strategy for robust detection of insertions, deletions, and point mutations in CEBPA, a GC-rich content gene, using 454 next-generation deep-sequencing technology
    Vera Grossmann
    MLL Munich Leukemia Laboratory, Munich, Germany
    J Mol Diagn 13:129-36. 2011
    ..In conclusion, next-generation amplicon sequencing enables the highly sensitive detection of molecular mutations and is a feasible assay for routine assessment of GC-rich content amplicons...
  51. ncbi request reprint Acute myeloid leukemia with a complex aberrant karyotype is a distinct biological entity characterized by genomic imbalances and a specific gene expression profile
    Claudia Schoch
    Laboratory for Leukemia Diagnostics, University Hospital Grosshadern, Ludwig Maximilians University, Munich, Germany
    Genes Chromosomes Cancer 43:227-38. 2005
    ..These data may be the basis for developing targeted therapeutic strategies to increase the cure rate in patients with AML and a complex aberrant karyotype...
  52. doi request reprint Biological and clinical characterization of recurrent 14q deletions in CLL and other mature B-cell neoplasms
    Lena Reindl
    Munich Leukemia Laboratory, Munich Interdisciplinary Clinic for Stem Cell Transplantation, Max Lebsche Platz 31, Munich, Germany
    Br J Haematol 151:25-36. 2010
    ..80·1 months, P = 0·015). In conclusion, the del(14q) is a rare recurrent alteration in diverse mature B-cell neoplasms, shows variable size but distinct clustering of breakpoints, and is associated with short time to treatment...
  53. pmc The AML1-ETO fusion gene and the FLT3 length mutation collaborate in inducing acute leukemia in mice
    Christina Schessl
    Clinical Cooperative Group Leukemia, National Research Center for Environment and Health GSF, Munich, Germany
    J Clin Invest 115:2159-68. 2005
    ....
  54. pmc Use of CBL exon 8 and 9 mutations in diagnosis of myeloproliferative neoplasms and myelodysplastic/myeloproliferative disorders: an analysis of 636 cases
    Susanne Schnittger
    MLL Munich Leukemia Laboratory, Max Lebsche Platz 31, 81377 Munich, Germany
    Haematologica 97:1890-4. 2012
    ..Therefore, CBL(mut) are frequent in chronic myelomonocytic leukemia, absent in classical myeloproliferative neoplasms, and are only exceptionally found in coincidence with JAK-STAT pathway activating mutations...
  55. doi request reprint Evaluation of flow cytometric assessment of myeloid nuclear differentiation antigen expression as a diagnostic marker for myelodysplastic syndromes in a series of 269 patients
    Frauke Bellos
    MLL Munich Leukemia Laboratory, Munich, Germany
    Cytometry B Clin Cytom 82:295-304. 2012
    ..It is suggested to be expressed more weakly in patients with myelodysplastic syndromes (MDS). The analysis of MNDA therefore may improve diagnostic capabilities of multiparameter flow cytometry (MFC) in MDS...
  56. pmc Prognostic relevance of RUNX1 mutations in T-cell acute lymphoblastic leukemia
    Vera Grossmann
    MLL Munich Leukemia Laboratory, Max Lebsche Platz 31, 81377 Munich, Germany
    Haematologica 96:1874-7. 2011
    ..043). In conclusion, RUNX1 mutations are an important novel biomarker for a comprehensive characterization of T-cell acute lymphoblastic leukemia with poor prognostic impact and have implications for use also in monitoring disease...
  57. ncbi request reprint Feasibility of using the combined MDS-EVI1/EVI1 gene expression as an alternative molecular marker in acute myeloid leukemia: a report of four cases
    Martin Weisser
    Medical Department III, Klinikum Grosshadern, Ludwig Maximilians University, Marchioninistrasse 15, 81377 Munich, Germany
    Cancer Genet Cytogenet 177:64-9. 2007
    ..In conclusion, the combined MDS-EVI1/EVI1 gene may serve as an alternative MRD marker in AML, especially in samples where other specific markers are lacking...
  58. ncbi request reprint Diagnostic pathways in acute leukemias: a proposal for a multimodal approach
    Torsten Haferlach
    MLL Munich Leukemia Laboratory, Munich, Germany
    Ann Hematol 86:311-27. 2007
    ....
  59. ncbi request reprint Acute myeloid leukemia (AML) with t(8;21)(q22;q22) relapsing as AML with t(3;21)(q26;q22)
    Ulrike Bacher
    Department of Clinical Chemistry, Ludwig Maximilians University of Munich, Marchioninistrasse 15, 81377 Munich, Germany
    Cancer Genet Cytogenet 168:172-4. 2006
    ..These data suggest that this patient developed a secondary therapy-related AML rather than a relapse...
  60. ncbi request reprint Translocations as a mechanism for homozygous deletion of 13q14 and loss of the ATM gene in a patient with B-cell chronic lymphocytic leukemia
    Hannes Herholz
    MLL Munich Leukemia Laboratory, Max Lebsche Platz 31, 81377 Munich, Germany
    Cancer Genet Cytogenet 174:57-60. 2007
    ..Deleted sites on 13q14 appeared to be located within the breakpoint regions of the translocations. We show that mechanisms other than interstitial deletions may lead to loss of critical chromosomal regions in CLL...
  61. ncbi request reprint Morphologic dysplasia in de novo acute myeloid leukemia (AML) is related to unfavorable cytogenetics but has no independent prognostic relevance under the conditions of intensive induction therapy: results of a multiparameter analysis from the German AML
    Torsten Haferlach
    Department of Medicine III, Ludwig Maximilians University, Grosshadern, Munich, Germany
    J Clin Oncol 21:256-65. 2003
    ..We also assessed the clinical significance of the recently introduced World Health Organization (WHO) classification for AML, which proposed dysplasia as a new parameter for classification...
  62. ncbi request reprint Role of gene expression profiling for diagnosing acute leukemias
    Wolfgang Kern
    Laboratory for Leukemia Diagnostics, Department of Internal Medicine III, University Hospital Grosshadern, Munich, Germany
    Rev Clin Exp Hematol 9:E1. 2005
    ..Furthermore, it is anticipated that new biologically defined and clinically relevant subtypes of leukemia will be identified based on gene expression profiling. This method may therefore guide therapeutic decisions...
  63. ncbi request reprint Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype
    Susanne Schnittger
    Department of Internal Medicine III, University Hospital Grosshadern, Ludwig Maximilian s University, Munich, Germany
    Blood 106:3733-9. 2005
    ..In conclusion, this study demonstrates that NPM1+/FLT3-LM- mutations are an independent predictor for a favorable outcome in AML with normal karyotype...
  64. ncbi request reprint Gene expression profiling as a tool for the diagnosis of acute leukemias
    Torsten Haferlach
    Department of Internal Medicine III, University Hospital Grosshadern, Munich, Germany
    Semin Hematol 40:281-95. 2003
    ..Gene expression profiling should also lead to the detection of new biological and clinically relevant subtypes in leukemia and therefore guide therapeutic decisions...
  65. ncbi request reprint The protein tyrosine kinase inhibitor SU5614 inhibits FLT3 and induces growth arrest and apoptosis in AML-derived cell lines expressing a constitutively activated FLT3
    Karsten Spiekermann
    Department of Medicine III, University Hospital Grosshadern, Clinical Cooperative Group Leukemia, GSF National Research Center for Environment and Health, Munich, Germany
    Blood 101:1494-504. 2003
    ..The selective and potent cytotoxicity of FLT3 PTK inhibitors support a clinical strategy of targeting FLT3 as a new molecular treatment option for patients with FLT3-LM/TKD-mutation(+) AML...
  66. ncbi request reprint Point mutations in the juxtamembrane domain of FLT3 define a new class of activating mutations in AML
    Carola Reindl
    Department of Medicine III, University Hospital Grosshadern, CCG Leukemia, GSF National Research Center for Environment and Health, Marchioninistr 25, 81377 Munich, Germany
    Blood 107:3700-7. 2006
    ....
  67. ncbi request reprint Stability of leukemia-associated aberrant immunophenotypes in patients with acute myeloid leukemia between diagnosis and relapse: comparison with cytomorphologic, cytogenetic, and molecular genetic findings
    Daniela Voskova
    Laboratory for Leukemia Diagnostics, Department of Internal Medicine III, University Hospital Grosshadern, Ludwig Maximilians University, Munich, Germany
    Cytometry B Clin Cytom 62:25-38. 2004
    ..Changes in LAIPs during the course of the disease may be a limitation for this approach...
  68. doi request reprint Development and validation of a real-time quantification assay to detect and monitor BRAFV600E mutations in hairy cell leukemia
    Susanne Schnittger
    MLL Munich Leukemia Laboratory, Munich, Germany
    Blood 119:3151-4. 2012
    ..001). In conclusion, we confirmed BRAFmut as a useful marker in HCL, its absence in HCL variant, and developed an RT-PCR-based assay to monitor minimal residual disease in HCL...
  69. doi request reprint IDH1 mutations are detected in 6.6% of 1414 AML patients and are associated with intermediate risk karyotype and unfavorable prognosis in adults younger than 60 years and unmutated NPM1 status
    Susanne Schnittger
    Munich Leukemia Laboratory, Munich, Germany
    Blood 116:5486-96. 2010
    ..039) especially in the age group < 60 years (P = .028). In conclusion, these data show that IDH1R132 may significantly add information regarding characterization and prognostication in AML...
  70. ncbi request reprint AML with 11q23/MLL abnormalities as defined by the WHO classification: incidence, partner chromosomes, FAB subtype, age distribution, and prognostic impact in an unselected series of 1897 cytogenetically analyzed AML cases
    Claudia Schoch
    Laboratory for Leukemia Diagnostics, Department of Internal Medicine III, University Hospital Grosshadern, Ludwig Maximilians University of Munich, Marchioninistr 15, 81377 Munchen, Germany
    Blood 102:2395-402. 2003
    ..0 vs 8.9 months, P =.36). In conclusion, the category AML with 11q23/MLL abnormalities accounts for 2.8% of unselected AML, is closely associated with monocytic differentiation, and has a dismal prognosis. (..
  71. ncbi request reprint Cytogenetics, fluorescence in situ hybridization, and reverse transcriptase polymerase chain reaction are necessary to clarify the various mechanisms leading to an MLL-AF10 fusion in acute myelocytic leukemia with 10;11 rearrangement
    Mirjam Klaus
    Department of Internal Medicine III, Laboratory for Leukemia Diagnostics, Ludwig Maximilians University, 81377 Munich, Germany
    Cancer Genet Cytogenet 144:36-43. 2003
    ..Compared to translocations involving MLL and other partner genes, complex rearrangements are unique for MLL-AF10 fusions. This may result from the opposite orientation of MLL and AF10...
  72. ncbi request reprint Impact of integrating clinical and genetic information
    Martin Dugas
    Department of Medical Informatics, Biometrics and Epidemiology IBE, University of Munich, Marchioninistr 15, D 81377 Munich, Germany
    In Silico Biol 2:383-91. 2002
    ....
  73. ncbi request reprint A new and recurrent activating length mutation in exon 20 of the FLT3 gene in acute myeloid leukemia
    Karsten Spiekermann
    Clinical Cooperative Group Leukemia, GSF, National Research Center for Environment and Health, University Hospital Grosshadern, Ludwig Maximilians University, Marchioninistrasse 15, 81377 Munich, Germany
    Blood 100:3423-5. 2002
    ..Our results show for the first time that in addition to known mutations in the JM and the catalytic domain, further activating length mutations exist in the FLT3 gene...
  74. ncbi request reprint Gene expression profiling as a diagnostic tool in acute myeloid leukemia
    Wolfgang Kern
    Laboratory for Leukemia Diagnostics, Department of Internal Medicine III, University Hospital Grosshadern, Munich, Germany
    Am J Pharmacogenomics 4:225-37. 2004
    ..Furthermore, gene expression profiling may also lead to the detection of new biologically defined and clinically relevant subtypes in leukemia and guide therapeutic decision-making in the future...
  75. ncbi request reprint Risk assessment by monitoring expression levels of partial tandem duplications in the MLL gene in acute myeloid leukemia during therapy
    Martin Weisser
    Laboratory for Leukemia Diagnostics, Medical Department III, Klinikum Grosshadern, Ludwig Maximilians University, Munich, Germany
    Haematologica 90:881-9. 2005
    ....
  76. ncbi request reprint Monitoring of minimal residual disease in acute myeloid leukemia
    Wolfgang Kern
    Laboratory for Leukemia Diagnostics, Ludwig Maximilians University, University Hospital Grosshadern, Department of Internal Medicine III, 81366 Muenchen, Germany
    Crit Rev Oncol Hematol 56:283-309. 2005
    ..Thus, it is desirable to establish new molecular markers for PCR-based studies. Large clinical trials will determine the role and place of immunologic and PCR-based monitoring in the prognostic stratification of patients with AML...
  77. ncbi request reprint Further correlations of morphology according to FAB and WHO classification to cytogenetics in de novo acute myeloid leukemia: a study on 2,235 patients
    Ulrike Bacher
    Laboratory for Leukemia Diagnostics, Department for Internal Medicine III, University Hospital Grosshadern, Ludwig Maximilians University, Marchioninistr 15, 81377, Munich, Germany
    Ann Hematol 84:785-91. 2005
    ..In conclusion, the central role of morphology as defined by the FAB and WHO classification in AML at diagnosis is still justified in combination with other techniques...
  78. ncbi request reprint A combination of cytomorphology, cytogenetic analysis, fluorescence in situ hybridization and reverse transcriptase polymerase chain reaction for establishing clonality in cases of persisting hypereosinophilia
    Ulrike Bacher
    Department of Clinical Chemistry, Ludwig Maximilians University, Munich Marchioninistr 15, 81377 Munich
    Haematologica 91:817-20. 2006
    ..A FIP1L1-PDGFRA fusion gene was identified in four male patients by interphase FISH and RT-PCR. These methods in combination demonstrated clonality in 8/40 patients (20%) with a male predominance (6/8; 75%)...
  79. ncbi request reprint Monitoring of minimal residual disease in acute myeloid leukemia
    Wolfgang Kern
    MLL Munich Leukemia Laboratory, Munich, Germany
    Cancer 112:4-16. 2008
    ..Large clinical trials will determine the exact role and place of immunologic and RQ-PCR-based monitoring of MRD in the therapy of patients with AML...
  80. ncbi request reprint Distinct genetic patterns can be identified in acute monoblastic and acute monocytic leukaemia (FAB AML M5a and M5b): a study of 124 patients
    Torsten Haferlach
    Department of Internal Medicine III, Laboratory for Leukaemia Diagnostics, University Hospital Grosshadern, Ludwig Maximilians University, Marchioninistrasse 15, 81377 Munich, Germany
    Br J Haematol 118:426-31. 2002
    ..In conclusion, we demonstrated genetic, i.e. biological, differences between AML M5a and AML M5b and all other AML. Therefore, AML M5 should further be categorized as two different groups, as proposed by the WHO classification...
  81. pmc Acute myeloid leukemias with reciprocal rearrangements can be distinguished by specific gene expression profiles
    Claudia Schoch
    Laboratory for Leukemia Diagnostics, Department of Internal Medicine III, University Hospital Grosshadern, Ludwig Maximilians University, 81366 Munich, Germany
    Proc Natl Acad Sci U S A 99:10008-13. 2002
    ..By using two different strategies for microarray data analyses, this study revealed a unique correlation between AML-specific cytogenetic aberrations and gene expression profiles...
  82. ncbi request reprint Blast count and cytogenetics correlate and are useful parameters for the evaluation of different phases in chronic myeloid leukemia
    Ulrike Bacher
    Laboratory for Leukemia Diagnostics, Department for Internal Medicine III, Klinikum Grossharden, Ludwig Maximilians University, Marchioninistr, Munich, Germany
    Leuk Lymphoma 46:357-66. 2005
    ..We therefore propose to focus staging systems of CML on the correlation of the percentage of bone marrow blasts and the cytogenetic results...
  83. ncbi request reprint Immunostimulatory oligonucleotide-induced metaphase cytogenetics detect chromosomal aberrations in 80% of CLL patients: A study of 132 CLL cases with correlation to FISH, IgVH status, and CD38 expression
    Frank Dicker
    MLL Munich Leukemia Laboratory GmbH, Max Lebsche Platz 31, 81377 Munich, Germany
    Blood 108:3152-60. 2006
    ..We demonstrate that FISH analysis underestimates the complexity of chromosomal aberrations in CLL. Therefore, conventional cytogenetics may define subgroups of patients with high risk of progression...
  84. ncbi request reprint Additional clonal abnormalities in Philadelphia-positive ALL and CML demonstrate a different cytogenetic pattern at diagnosis and follow different pathways at progression
    Ulrike Bacher
    Laboratory for Leukemia Diagnostics, Department for Internal Medicine III, Klinikum Grosshadern, Ludwig Maximilians University, Marchioninistrasse 15, D 81377 Munich, Germany
    Cancer Genet Cytogenet 157:53-61. 2005
    ..In conclusion, we were able to demonstrate that the cytogenetic patterns of Ph+ ALL and of CML are different at diagnosis and furthermore follow different pathways during progression or relapse...
  85. ncbi request reprint Global approach to the diagnosis of leukemia using gene expression profiling
    Torsten Haferlach
    Laboratory for Leukemia Diagnostics, Department of Internal Medicine III, Ludwig Maximilians University, Marchioninistr 15, 81377 Munich
    Blood 106:1189-98. 2005
    ..Accordingly, cluster analysis completely separated all 13 subgroups analyzed. Gene expression profiling can predict all clinically relevant subentities of leukemia with high accuracy...
  86. ncbi request reprint Monitoring of acute myeloid leukemia by flow cytometry
    Wolfgang Kern
    Laboratory for Leukemia Diagnostics, Ludwig Maximilians University, University Hospital Grosshadern, Department of Internal Medicine III, 81366 Munich, Germany
    Curr Oncol Rep 5:405-12. 2003
    ..Large clinical trials will determine the role of immunologic monitoring in the prognostic stratification of patients with AML...
  87. ncbi request reprint Detection of t(14;18)(q32;q21) in B-cell chronic lymphocytic leukemia
    Wolfgang Kern
    Laboratory for Leukemia Diagnostics, Department of Internal Medicine III, University Hospital Grosshadern, Ludwig Maximilians University, Muenchen, Germany
    Arch Pathol Lab Med 129:410-1. 2005
    ..Therapy is highly diverse between both diseases. We describe a case with cytomorphologically and immunologically proven B-cell chronic lymphocytic leukemia in which t(14;18)(q32;q21) was found...
  88. ncbi request reprint Conventional cytogenetics of myeloproliferative diseases other than CML contribute valid information
    Ulrike Bacher
    Laboratory for Leukemia Diagnostics, Department for Internal Medicine III, Klinikum Grosshadern, Ludwig Maximilians University, Marchioninistrasse 15, 81377 Munich, Germany
    Ann Hematol 84:250-7. 2005
    ..In ET and in HES the aberration rate was only 3 and 7%, respectively. Thus, cytogenetics can be omitted. However, in some of these cases molecular procedures should be integrated into the routine diagnostic process...
  89. ncbi request reprint Population-based age-specific incidences of cytogenetic subgroups of acute myeloid leukemia
    Ulrike Bacher
    Department for Internal Medicine III, Klinikum, Grosshadern, Ludwig Maximilians University, Munich, Germany
    Haematologica 90:1502-10. 2005
    ..However, detailed data on the population-based age-dependent incidences of distinct cytogenetic subtypes as well as of molecular mutations are lacking...
  90. ncbi request reprint Increased risk for therapy-associated hematologic malignancies in patients with carcinoma of the breast and combined homozygous gene deletions of glutathione transferases M1 and T1
    Detlef Haase
    Department of Hematology and Oncology, Georg August University, Robert Koch Strasse 40, 37075 Gottingen, Germany
    Leuk Res 26:249-54. 2002
    ..An insufficient detoxification of cytostatic drugs such as cyclophosphamide is suggested to represent the underlying pathomechanism...
  91. ncbi request reprint Distinct gene expression patterns associated with FLT3- and NRAS-activating mutations in acute myeloid leukemia with normal karyotype
    Kai Neben
    Division of Molecular Genetics B060, Deutsches Krebsforschungszentrum, Im Neuenheimer Feld 280, D 69120 Heidelberg, Germany
    Oncogene 24:1580-8. 2005
    ..In conclusion, we showed that unique gene expression patterns can be correlated with FLT3-ITD and FLT3-TKD. This might lead to the identification of further pathogenetic relevant candidate genes particularly in AML with normal karyotype...
  92. ncbi request reprint Prognosis in therapy-related acute myeloid leukemia and impact of karyotype
    Wolfgang Kern
    J Clin Oncol 22:2510-1. 2004
  93. ncbi request reprint Treatment of older patients with AML
    Thomas Buchner
    University Hospital, Department of Medicine, Hematology and Oncology, Albert Schweitzer Str 33, D 48129 Munster, Germany
    Crit Rev Oncol Hematol 56:247-59. 2005
    ..This finding did not vary by age under or above 60 years. Given the actual median age in this disease being more than 60 years the adequate management of older age AML remains as the major challenge...
  94. ncbi request reprint A multicenter evaluation of comprehensive analysis of MLL translocations and fusion gene partners in acute leukemia using the MLL FusionChip device
    Christine J Harrison
    Leukaemia Research Cytogenetics Group, Cancer Sciences Division, University of Southampton, MP 822 Duthie Building, Southampton General Hospital, Southampton SO16 6YD, UK
    Cancer Genet Cytogenet 173:17-22. 2007
    ..The type of molecular information provided by MLL FusionChip gave an indication of the appropriate primers to design for disease monitoring of MLL patients following treatment...
  95. pmc Diagnostic tool for the identification of MLL rearrangements including unknown partner genes
    Claus Meyer
    Institute of Pharmaceutical Biology Center for Drug Research, Development and Safety ZAFES, Biocenter, University of Frankfurt, D 60439 Frankfurt Main, Germany
    Proc Natl Acad Sci U S A 102:449-54. 2005
    ..Furthermore, the determined patient-specific fusion sequences are useful for minimal residual disease monitoring of MLL associated acute leukemias...
  96. ncbi request reprint Distinct sequences on 11q13.5 and 11q23-24 are frequently coamplified with MLL in complexly organized 11q amplicons in AML/MDS patients
    Andrea Zatkova
    Institut für Medizinische Biologie, Universitat Wien, Wien, Austria
    Genes Chromosomes Cancer 39:263-76. 2004
    ..Thus, we demonstrated that 11q amplicons in AML/MDS patients display a complex organization and have provided evidence for coamplification of two additional regions on the long arm of chromosome 11 that may harbor candidate target genes...
  97. ncbi request reprint Double induction containing either two courses or one course of high-dose cytarabine plus mitoxantrone and postremission therapy by either autologous stem-cell transplantation or by prolonged maintenance for acute myeloid leukemia
    Thomas Buchner
    Department of Medicine, Hematology Oncology, University of Muenster, Muenster, Germany
    J Clin Oncol 24:2480-9. 2006
    ..Whether additional intensification can add to this effect has not yet been determined...
  98. doi request reprint NPM1 mutations and cytoplasmic nucleophosmin are mutually exclusive of recurrent genetic abnormalities: a comparative analysis of 2562 patients with acute myeloid leukemia
    Brunangelo Falini
    Institute of Hematology, University of Perugia, Perugia, Italy
    Haematologica 93:439-42. 2008
    ..Taken together, these findings make NPMc+ acute myeloid leukemia a good candidate for inclusion in the upcoming World Health Organization classification...
  99. ncbi request reprint Acute myeloid leukemia with recurring chromosome abnormalities as defined by the WHO-classification: incidence of subgroups, additional genetic abnormalities, FAB subtypes and age distribution in an unselected series of 1,897 patients with acute myeloid l
    Claudia Schoch
    Haematologica 88:351-2. 2003
  100. ncbi request reprint Prognostic relevance of FLT3-TKD mutations in AML: the combination matters--an analysis of 3082 patients
    Ulrike Bacher
    Bone Marrow Transplant Unit, University Hospital of Hamburg Eppendorf, Hamburg, Germany
    Blood 111:2527-37. 2008
    ..In contrast, we found an additional favorable impact of FLT3-TKD on EFS in prognostically favorable AML with NPM1- or CEBPA mutations...
  101. ncbi request reprint Absence of SCL mutations in myeloid malignancies
    Eric Delabesse
    University of Cambridge, Department of Haematology, Cambridge Institute for Medical Research, Cambridge, UK
    Br J Haematol 120:482-3. 2003
    ..We searched for SCL mutations in myeloid leukaemias and chronic myeloproliferative disorders. Our data demonstrated that SCL point mutations were rare in acute myeloid leukaemia and myeloproliferative disorders...